Fate Therapeutics (FATE)

$1.16 -0.07 (-5.69%)
Market Cap 137.27M
Revenue (ttm) 13.63M
Net Income (ttm) -186.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,366.54%
Debt to Equity Ratio 0.00
Volume 2,401,900
Avg Vol 1,515,352
Day's Range N/A - N/A
Shares Out 115.35M
Stochastic %K 27%
Beta 2.22
Analysts Sell
Price Target $4.94

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus eryt...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 875 1800
Address:
12278 Scripps Summit Drive, San Diego, United States
Rocketman808
Rocketman808 Feb. 3 at 10:27 PM
$FATE $1.10 would be nice or $1.05. i still dont think I own enough. it’s not enough until investor relations is reaching out to me 🤓
1 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Feb. 3 at 8:39 PM
added few more today. catalysts/cash plays $TOVX $FATE $TCRX $VTGN $AZTR
0 · Reply
Vomiman
Vomiman Feb. 3 at 6:28 PM
$FATE cringe day
0 · Reply
Nik7777
Nik7777 Feb. 3 at 2:59 PM
$FATE Have a good day !
0 · Reply
Nik7777
Nik7777 Feb. 3 at 2:58 PM
$FATE
0 · Reply
StockDaddy68
StockDaddy68 Feb. 3 at 1:08 PM
$FATE
0 · Reply
Jake140
Jake140 Feb. 3 at 9:25 AM
$FATE
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 7:38 PM
$FATE RSI: 60.48, MACD: 0.0458 Vol: 0.09, MA20: 1.14, MA50: 1.09 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ils85
ils85 Feb. 2 at 6:58 PM
$FATE 5+ incoming
1 · Reply
ils85
ils85 Feb. 2 at 6:53 PM
$FATE added
0 · Reply
Latest News on FATE
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Feb 3, 2026, 4:05 PM EST - 9 hours ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Jan 5, 2026, 4:05 PM EST - 4 weeks ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 2 months ago

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 13, 2025, 8:30 AM EST - 2 months ago

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Oct 26, 2025, 11:30 AM EDT - 3 months ago

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Aug 12, 2025, 4:01 PM EDT - 6 months ago

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

Jun 11, 2025, 9:00 AM EDT - 8 months ago

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 30, 2025, 4:30 PM EDT - 8 months ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 28, 2025, 5:54 PM EDT - 8 months ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 13, 2025, 4:01 PM EDT - 9 months ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector

May 8, 2025, 6:22 PM EDT - 9 months ago

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Apr 29, 2025, 9:25 AM EDT - 10 months ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Apr 14, 2025, 8:00 AM EDT - 10 months ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 5, 2025, 4:01 PM EST - 11 months ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mar 4, 2025, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics to Present at Upcoming Investor Conferences

Feb 14, 2025, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Feb 4, 2025, 7:41 PM EST - 1 year ago

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Dec 9, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Fate Therapeutics Announces Leadership Transition

Nov 29, 2024, 1:05 PM EST - 1 year ago

Fate Therapeutics Announces Leadership Transition

Fate Therapeutics to Present at Upcoming December Investor Conferences

Nov 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Nov 20, 2024, 4:34 PM EST - 1 year ago

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Nov 18, 2024, 8:05 AM EST - 1 year ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 12, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Nov 9, 2024, 1:30 PM EST - 1 year ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Nov 8, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 29, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

May 11, 2024, 6:12 PM EDT - 1 year ago

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 9, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 9, 2024, 8:30 AM EDT - 1 year ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

May 3, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom

Apr 29, 2024, 4:48 PM EDT - 1 year ago

Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 29, 2024, 12:09 PM EDT - 1 year ago

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Mar 19, 2024, 8:44 AM EDT - 2 years ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Fate Therapeutics to Present at Upcoming March Investor Conferences

Mar 1, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Present at Upcoming March Investor Conferences

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 8:25 PM EST - 2 years ago

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 26, 2024, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 13, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics: Getting There, But Perpetually

Nov 12, 2023, 12:10 PM EST - 2 years ago

Fate Therapeutics: Getting There, But Perpetually

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 9:12 PM EST - 2 years ago

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Nov 8, 2023, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Fate Therapeutics to Present at Upcoming September Investor Conferences

Aug 31, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Present at Upcoming September Investor Conferences

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 11:37 PM EDT - 2 years ago

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

Jul 28, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

Rocketman808
Rocketman808 Feb. 3 at 10:27 PM
$FATE $1.10 would be nice or $1.05. i still dont think I own enough. it’s not enough until investor relations is reaching out to me 🤓
1 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Feb. 3 at 8:39 PM
added few more today. catalysts/cash plays $TOVX $FATE $TCRX $VTGN $AZTR
0 · Reply
Vomiman
Vomiman Feb. 3 at 6:28 PM
$FATE cringe day
0 · Reply
Nik7777
Nik7777 Feb. 3 at 2:59 PM
$FATE Have a good day !
0 · Reply
Nik7777
Nik7777 Feb. 3 at 2:58 PM
$FATE
0 · Reply
StockDaddy68
StockDaddy68 Feb. 3 at 1:08 PM
$FATE
0 · Reply
Jake140
Jake140 Feb. 3 at 9:25 AM
$FATE
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 7:38 PM
$FATE RSI: 60.48, MACD: 0.0458 Vol: 0.09, MA20: 1.14, MA50: 1.09 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ils85
ils85 Feb. 2 at 6:58 PM
$FATE 5+ incoming
1 · Reply
ils85
ils85 Feb. 2 at 6:53 PM
$FATE added
0 · Reply
Rocketman808
Rocketman808 Feb. 2 at 4:21 PM
$FATE strapped in
0 · Reply
WestEgg
WestEgg Feb. 2 at 4:14 PM
$FATE May $1.50s call options are running!
0 · Reply
Jake140
Jake140 Feb. 2 at 11:43 AM
$FATE Morning All!
0 · Reply
StockDaddy68
StockDaddy68 Feb. 2 at 11:00 AM
$FATE Good morning everyone I hope y'all had a great weekend!
0 · Reply
Nik7777
Nik7777 Jan. 30 at 5:03 PM
$FATE I think the price will go up to 1.50 today!
1 · Reply
Farorm
Farorm Jan. 30 at 11:10 AM
$FATE market says no
0 · Reply
StockDaddy68
StockDaddy68 Jan. 30 at 10:41 AM
$FATE Good morning! Let's GOOOOOO on "Funky FATE Friday"
0 · Reply
vivalasvegasal
vivalasvegasal Jan. 29 at 11:37 PM
$FATE look how mamy shares vangaurd purchased!
1 · Reply
StockDaddy68
StockDaddy68 Jan. 29 at 6:35 PM
$FATE I'm LONG and I'm STRONG and down to get the friction on!!!
1 · Reply
Rocketman808
Rocketman808 Jan. 29 at 5:41 PM
$FATE messed with some nice nasdaq short this morning. rolling into the one and only! fed cuts around the corner
0 · Reply
Stocksprofessional
Stocksprofessional Jan. 29 at 4:30 PM
$FATE I’m officially all-in on two plays — FATE and CADL. Fully committed, holding with conviction, and staying long and strong for the ride ahead. 💪📈
3 · Reply
cta7978
cta7978 Jan. 29 at 4:01 PM
$FATE Tick Tock.. QR in about T-minus 20 trading sessions
0 · Reply